Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darovasertib neoadjuvant study in primary uveal melanoma
NL-OMON60558Phase 2Active, not recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of darovasertib in intraocular melanoma, sponsored by IDEAYA Biosciences. Started Jun 2024; status: active, not recruiting.
02
Drugs
darovasertib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on NL-OMON60558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60558.